Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethylhomospermine is a synthetic polyamine analogue and small molecule with antiproliferative and potential anti-diarrheal activities. It acts by antagonizing polyamine activity via the NMDA receptor glutamine binding site, modulating inotropic stasis and reducing stool volume. Diethylhomospermine also suppresses the activity of key biosynthetic enzymes in polyamine metabolism—ornithine decarboxylase and S-adenosylmethionine decarboxylase—which are important for cell proliferation. It has been investigated primarily for AIDS-related chronic diarrhea and HIV infections but development was discontinued due to toxicity concerns at higher doses (notably neurotoxicity and hepatic damage). The drug reached up to phase II clinical trials for these indications[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethylhomospermine.